Abstract
GoodRx Holdings, Inc. will release second-quarter 2026 results on August 5, 2026 Post Market; this preview outlines consensus expectations for revenue, earnings, and margins, reviews the prior quarter’s print, details the segment mix, and assesses the key factors likely to shape investor reaction and the prevailing analyst stance.
Market Forecast
Consensus for the second quarter points to total revenue of 193.16 million US dollars, a year-over-year change of -6.18%, adjusted EPS of 0.08 with a year-over-year change of -19.75%, and EBIT of 42.22 million US dollars with a year-over-year change of -21.31%; formal guidance for gross margin and net margin is not provided in the available forecasts. The main business is anchored by prescription transactions, which generated 113.69 million US dollars last quarter, and the company is prioritizing product monetization, user engagement, and cost discipline to support stability across the mix. The most promising segment remains manufacturer solutions, which delivered 52.23 million US dollars last quarter; given the consolidated revenue forecast is down year over year, the near-term segment comparison likely remains pressured before potential second-half improvements contingent on campaign activity.
Last Quarter Review
GoodRx Holdings, Inc. reported revenue of 194.01 million US dollars (down 4.42% year over year), a gross profit margin of 89.61%, GAAP net profit attributable to shareholders of 1.17 million US dollars for a net margin of 0.60%, and adjusted EPS of 0.07 (down 22.22% year over year). A notable highlight was revenue exceeding market expectations by 8.58 million US dollars (a positive variance of 4.63%), while EBIT of 39.39 million US dollars decreased 23.78% year over year and adjusted EPS tracked essentially in line with consensus. By segment, prescription transactions contributed 113.69 million US dollars, manufacturer solutions 52.23 million US dollars, subscriptions 24.39 million US dollars, and other revenue 3.69 million US dollars.
Current Quarter Outlook
Prescription transactions
Prescription transactions represent the core revenue stream and the primary lever for near-term earnings sensitivity. The key watch items this quarter include active user trends, coupon utilization rates, and realized take-rate per transaction, all of which influence both top-line trajectory and the relationship between revenue and cost of revenue. Given consensus implies a year-over-year decline in consolidated revenue, a stable or slightly improving sequential performance in prescription transactions would likely be interpreted as constructive, especially if the company demonstrates consistent unit economics per transaction. Management’s operating execution around marketing efficiency and audience quality should also be visible in the gross-to-net conversion dynamics; with a reported gross margin of 89.61% last quarter, investors will focus on whether that level is repeatable if promotional intensity is dialed either up or down to support volume. Finally, retailer and channel mix can affect realized economics and conversion, so color on progress with key partners and the breadth of coverage in the quarter could influence how the market extrapolates the prescription transactions contribution for the second half.
Manufacturer solutions
Manufacturer solutions remains the most promising growth vector given its ability to monetize branded campaign activity and patient engagement programs, and it contributed 52.23 million US dollars last quarter. The near-term setup likely reflects a balance between new and renewing brand programs and typical seasonal dynamics around campaign launches, which can tilt quarter-to-quarter revenue. With consensus for total company revenue down year over year in the second quarter, the segment’s year-over-year comparison may still be soft; however, clarity on the campaign pipeline and execution cadence for the second half could provide a path to improving growth as the year progresses. Investors will be looking for commentary on breadth of therapeutic categories supported, client retention across top customers, and the mix of solutions that may carry different margin profiles; all of these can affect both revenue durability and contribution margin. A clearer line of sight to signed campaigns and expected in-quarter revenue recognition would be especially supportive for sentiment because it frames the feasibility of meeting the full-year revenue range and shapes expectations for the trajectory into the third and fourth quarters.
Key stock price drivers this quarter
Guidance calibration versus the full-year revenue outlook is a central driver. The company indicated a full-year revenue range of 765.00 million to 785.00 million US dollars; if second-quarter revenue lands near the 193.16 million US dollars consensus, first-half revenue would approximate 387.17 million US dollars, leaving 377.83 million to 397.83 million US dollars needed in the second half to achieve the range. Commentary that increases confidence in second-half revenue cadence and operating leverage will likely carry significant weight with investors. Margin stewardship is another focal point: last quarter’s 89.61% gross margin sets a high bar, and investors will examine whether product and channel mix can sustain that level while adjusted EPS is under year-over-year pressure. Any signs of tighter expense control, especially around sales and marketing efficiency and G&A, can help mitigate EBIT and EPS headwinds implied by consensus. Finally, the relationship between user engagement, subscription attachment, and transaction frequency will matter for both growth and visibility; credibly linking initiatives that increase repeat usage with monetization metrics should improve confidence in the revenue run-rate exiting the quarter.
Analyst Opinions
The ratio of bullish to bearish opinions in the recent period skews bearish, with two notable firms expressing negative views and no offsetting positive calls, resulting in a 0% to 100% split. Barclays, through analyst Glen Santangelo, maintained a Sell rating and a 3.00 US dollars price target, highlighting concerns that align with current consensus softness in revenue and earnings for the quarter. Bank of America Securities, via analyst Allen Lutz, also maintained a Sell rating, citing a weakened long-term outlook and structural headwinds that may challenge the company’s ability to re-accelerate growth and expand margins at a pace that would shift the earnings trajectory. The majority view frames the second quarter as another period of transition in which consolidated revenue is anticipated to decline year over year and adjusted EPS is expected to remain below the prior-year level. These analysts are likely to focus on three proof points to change their stance: evidence that prescription transactions are stabilizing on a year-over-year basis, a clearly articulated and executable manufacturer solutions pipeline that can support sequential growth into the back half, and an operating plan that protects high gross margins while driving measurable improvements in EBIT and EPS. In this context, even if reported figures meet or slightly exceed consensus, management’s commentary around second-half revenue timing, campaign visibility, and expense optimization may matter more than the headline numbers for near-term stock reaction. Should the company communicate a tighter link between product improvements, user behavior, and monetization that credibly supports the 765.00 million to 785.00 million US dollars full-year outlook, it could begin to address the core issues cited by bearish analysts and help reset expectations for 2026 trends. Conversely, if the update implies continued pressure on year-over-year comparisons without incremental visibility, the majority view would likely persist as the reference point for investor positioning.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments